A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis (COLIBRI)
Ulcerative Colitis in Subjects of Clinical Routine: A Four Year, Multicenter, Prospective, Non-Interventional Study to Evaluate Utilization, Effectiveness, and Quality of Life With Ozanimod
Sponsor: Bristol-Myers Squibb
Terminated
Business objectives have changed
Other terminated trials from Bristol-Myers Squibb
Other Colitis, Ulcerative trials with similar outcome
A observational or N/A phase clinical study on Colitis, Ulcerative, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Aug 2025 — Present [monthly]
Terminated
Status: Recruiting → Terminated
-
Sep 2024 — Aug 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2022 — Jul 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .